Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

Amphastar's Q4 sales grew 20% to $186.5M, missing estimates. Primatene MIST surpassed $100M in annual sales, while Baqsimi saw strong growth.

As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, Kamada Ltd (NASDAQ: KMDA), plays an important role in helping address rare ...

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report) yesterday and set a price ...

The S&P 500 (SP500) hit new highs during February trade, but that wasn’t enough to stave off a monthly loss. The benchmark ...

Stanley Druckenmiller is a retired hedge fund manager of Duquesne Capital, which focuses on macro investment strategy. His fund constantly delivered high returns, and in 2010, when the fund failed to ...

South Korean vaccine maker SK bioscience today revealed that it has received prior notification from the Pan American Health ...

The rising prevalence of respiratory diseases and technological advancements drive significant market growth.Pune, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Aerosol Drug Delivery Devices Market Size & Growth ...

Corneal Ulcer Treatment MarketThe global corneal ulcer treatment market is projected to grow at a CAGR of 5.2% from 2024 to 2034, reaching a market value of USD 1,601.1 million by 2034. In 2024, the ...

The global seasonal affective disorder therapeutics market is set for steady growth, with revenue projected to reach USD ...